HighTower Advisors
RXII

HighTower Advisors’s GALENA BIOPHARMA INC COM RXII Stock Holding History

HighTower Advisors’s Portfolio RXII Stock Details RXII Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-26,000
Closed -$1K – 1668
2013
Q3 		$1K Buy
+26,000
New +$1K ﹤0.01% 1344

Other funds holding RXII

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
U
UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return

HighTower Advisors's RXII Position: Q4 2013 in Review

HighTower Advisors sold out of GALENA BIOPHARMA INC COM (RXII) in Q4 2013, closing a stake of 25,284 shares — an estimated $58K sold.

HighTower Advisors first reported a position in RXII in Q3 2013 and held it in 1 quarter. The position peaked at $58K in Q3 2013. 76 funds tracked by Wall St. Rank hold RXII as of Q4 2013.

  • HighTower Advisors reported no remaining GALENA BIOPHARMA INC COM position as of Q4 2013 after selling out during the quarter.
  • HighTower Advisors sold 25,284 GALENA BIOPHARMA INC COM shares in Q4 2013, an estimated $58K.
  • HighTower Advisors first reported a position in GALENA BIOPHARMA INC COM in Q3 2013 and held it in 1 quarter.
  • HighTower Advisors's GALENA BIOPHARMA INC COM position peaked at $58K in Q3 2013.
  • 76 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q4 2013.

Based on HighTower Advisors's 13F filing for Q4 2013, filed 14 Feb 2014.